When was OncoMark founded?

OncoMark was founded in 2011 and raised its 1st funding round 3 years after it was founded.

Where is OncoMark located?

OncoMark is headquartered in Dublin, Ireland.

How many employees does OncoMark have?

As of May 31, 2026, the latest employee count at OncoMark is 3.

Is OncoMark a funded company?

OncoMark is a funded company, having raised a total of $6.72M across 5 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Dec 01, 2014.

When was the latest funding round of OncoMark?

OncoMark's latest funding was a $***** Series A round on Jul 19, 2019, with participation from 2 investors. Its primary sector is Genomics. In Ireland, the Genomics sector has seen $39M in funding in 2026 to date.

Where does OncoMark rank among its competitors?

OncoMark ranks 77th amongst 196 active competitors, of which 61 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was ScreenPoint, which secured $14M in Apr, 2026.

Who are the top competitors of OncoMark?

OncoMark's top competitors include Molbio Diagnostics, ScreenPoint and Biocartis. Among them, ScreenPoint secured the most recent funding round in April, 2026.

OncoMark - 2026 Company Profile, Team, Funding & Competitors

Company Details

Oncomark develops tissue-based diagnostics for cancer. The company's flagship product OncoMasTR qPCR assay uses various genes and control genes to give the prognostic risk of recurrence in early-stage breast cancer patients. In addition, the company is developing products for melanoma, colorectal cancer, and prostate cancer.

Website: oncomark.com
Social

Key Metrics

Founded Year

2011

Location

Dublin, Ireland

Stage

Acqui-Hired

Total Funding

$6.72M in 5 rounds

Latest Funding Round

Series A, Jul 19, 2019, $*****

Investors

Halo Business Angel Network & 5 more

Ranked

77^th among 196 active competitors

Employee Count

3 as on May 31, 2026

Similar Companies

Molbio Diagnostics & 153 more

View OncoMark's full profile

OncoMark has raised a total funding of $6.72M over 5 rounds. Its first funding round was on Dec 01, 2014. Its latest funding round was a Series A round on Jul 19, 2019 for $*****. 2 investors participated in its latest round. OncoMark has 6 institutional investors.

Here is the list of recent funding rounds of OncoMark:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 19, 2019	2857393	Series A	2536364	7970365	7570516	8237479
Feb 15, 2017	9930874	Seed	6473799	2148076	7111096	Kernel Capital & 3 more
Feb 01, 2016	9488892	Grant (prize money)	9542215	2362660	4298123	Europa

Access funding benchmarks and valuations. Sign up today!

View details of OncoMark's funding rounds and investors

The founders of OncoMark is William Gallagher.

Here are the details of OncoMark's key team members:

William Gallagher: Co-Founder & CSO of OncoMark.

View details of OncoMark's Founder profiles and Board Members

OncoMark's employee count trend

OncoMark has 3 employees as of May 26. Here is OncoMark's employee count trend over the years:

Uncover OncoMark's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of OncoMark include Molbio Diagnostics, ScreenPoint and Biocartis. Here is the list of Top 10 competitors of OncoMark, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Molbio Diagnostics 2000, Salcete (India), Series C	Developer of point-of-care molecular diagnostic platform for infectious disease detection	$124M	Motilal Oswal, Temasek & 36 others	71/100
2nd	ScreenPoint 2014, Nijmegen (Netherlands), Series C	Developer of artificial intelligence software for analyzing breast imaging mammograms	$47M	Insight Partners, Siemens & 3 others	63/100
3rd	Biocartis 2007, Mechelen (Belgium), Public	Developer of molecular assays for the detection of various diseases	$305M	Johnson & Johnson Innovation – JJDC, Advent Life Sciences ... & 18 others	58/100
4th	NeuMoDx 2012, Ann Arbor (United States), Acquired	Developer of a platform for low cost molecular testing	$66M	Arboretum Ventures, Wolverine Venture Fund ... & 3 others	58/100
5th	PreludeDx 2009, Laguna Hills (United States), Series B	Provider of risk assessment test for early stage breast cancer	$51.7M	Evidity Health Capital, GenesisCare & 2 others	57/100
6th	ChromaCode 2012, Carlsbad (United States), Series C	Digital molecular biology analytics for disease management	$95M	Northpond Ventures, New Enterprise Associates ... & 9 others	55/100
7th	Syantra Health 2013, Calgary (Canada), Series A	Developer of a blood test device to detect breast cancer	$10.4M	Accelerate Fund, Plug and Play Tech Center ... & 5 others	54/100
8th	DermTech 1996, San Diego (United States), Acquired	Provider of adhesive patch biopsy for skin cancer diagnostics	$24.4M	RTW Investments, Van Herk Groep & 3 others	54/100
9th	Biofire Diagnostics 1990, Salt Lake City (United States), Acquired	Provider of molecular diagnostic solutions for the detection of genetic conditions	$84M	Founders Fund, Athyrium Capital Management ... & 8 others	54/100
10th	Curasight 2013, Copenhagen (Denmark), Series A	Developer of PET ligands for breast cancer indications	$11.5M	PreSeed Ventures	53/100
77th	OncoMark 2011, Dublin (Ireland), Acqui-Hired	Provider of tissue-based diagnostics for cancer	$6.72M	Irrus Investments, Halo Business Angel Network ... & 4 others	31/100